

**UNIVERSITI TEKNOLOGI MARA**

**PRODUCTION OF GRISEOFULVIN  
NANOPARTICLES VIA WET-GRINDING METHOD**

**EKA GIYANTI PUTERI RAMLI**

Thesis submitted in fulfillment of the requirements

for the degree of

**Master of Science**

**Faculty of Pharmacy**

**September 2011**

## AUTHOR'S DECLARATION

I declare that the work in this thesis was carried out in accordance with the regulation of Universiti Teknologi MARA. It is original and is the result of my own work, unless otherwise indicated or acknowledged as referenced work. This thesis has not been submitted to any other academic institution or non-academic institution for any other degree or qualification.

I, hereby, acknowledge that I have been supplied with the Academic Rules and Regulations for Post Graduate, Universiti Teknologi MARA, regulating the conduct of my study and research.


Name of Student : Eka Giyanti Puteri Ramli

Student I.D. No. : 2008259198

Programme : Master of Science

Faculty : Pharmacy

Thesis Title : Production of Griseofulvin Nanoparticles Via Wet-Grinding Methods

Signature of Student :  .....

Date : September 2011

## ABSTRACT

Poorly water soluble drugs pose formulation problem and low oral bioavailability. Size reduction is among the several approaches to improve the solubility of such drugs. Wet grinding is a relatively new technology used to reduce the particle size down to sub-micron range. Griseofulvin a BCS II Class model drug was used to assess the feasibility of the above method to reduce the particle size to nanoscale with narrower distribution of particle size. Different factors such as type of the surfactants, concentration of surfactants, grinding speed, grinding time and the size of the grinding media (grinding beads) was varied to find the optimized conditions to achieve the desired particle size and size distribution of the griseofulvin particles. The lowest mean particle size of  $123 \pm 0.0$  nm for griseofulvin was accomplished with 5% w/v blend of 1.65% w/v of Tween 80 and 3.35% w/v of Span 80 at 1200 rpm using grinding media of 1 mm in diameter for 60 minutes followed by using 0.2 mm in diameter for 90 minutes (total 150 minutes). The next procedure considered the storage stability of nanosuspension. The type and concentration of stabilizers were varied. This study focused on the particle size growth control (Oswald ripening) during storage (monthly up to 3 months). The results showed that manitol 3% w/v used as a stabilizer could maintain the particle size at 158 nm with uniformity of 0.336 at 3 months storage condition (room temperature). *In vitro* dissolution rate of griseofulvin was significantly increased by reduction of particle size. Griseofulvin of different particle sizes rapidly dissolved in different dissolution media. The results showed that griseofulvin in nanosize almost 100 % dissolved in the aqueous solution after 120 minutes. The oral bioavailability of griseofulvin of different particle size was found to be significantly increased by reduction of particle size. The results showed that griseofulvin in nanosized form had greater bioavailability compared to the macrosized and microsized forms. The  $AUC_{(0-24)}$ ,  $C_{max}$ , and  $T_{max}$  of nanosized griseofulvin after oral administration were greater than the macrosized and microsized griseofulvin. The  $AUC_{(0-24)}$  of nanosized griseofulvin was one (1) fold greater than the microsized form and three (3) folds greater than the macrosized griseofulvin. The  $C_{max}$  of nanosized griseofulvin was one (1) fold of the macrosized form and two (2) folds of the microsized form. The  $T_{max}$  of the three (3) suspensions were not statistically significantly different. The tissue distribution study showed that a higher concentration of griseofulvin in tissues (kidney, liver, skin and brown adipose) was achieved by the nanosized griseofulvin than the macrosized griseofulvin. After two (2) hours of oral administration, the highest concentration of nanosized griseofulvin was found in the liver. This study shows that wet grinding is a possible method for the preparation of griseofulvin nanoparticles for improved oral bioavailability of this antibiotic.

## ACKNOWLEDGEMENTS

In the name of Allah SWT, I thank You for providing me with necessary strength, blessing perseverance, energy and good health for the completion of this study.

Thanks to my supervisor Prof. Dr. Abu Bakar Abd Majeed for his kindness in giving me this opportunity and supervising me to complete this work. Thanks to my co-supervisor Dr. Rosa Elizabeth Pereira for introducing me to nanotechnology, thanks for her advice and kindness to help me finish this thesis. Thanks to Mr. Tommy Julianto who kept an eye on the progress of my work. Thanks for every advice and for his kindness which has brought me to this opportunity.

I am also grateful to Prof. Dr. Aishah Adam, Dean of Faculty of Pharmacy and her staff for providing an excellent work environment during the past years and all the lab technicians for their unfailing assistance and patience.

Thanks to my colleague Liza binti Salleh, Suci Ameliya, Suhaili, Noreen Ang and Salizatul Liyana for the advice and the moments that we spent together completing our work and helping each other. Thanks to Noor Meliza, Sharifah Hendon Aljash (thank you for everything sha), Faizal, Farid, Faisal, Shah Nizam and everyone who has helped me on this project. Sharing anything with them always benefited me tremendously both in academic and in real-life and also has shown support that a friend could ever ask for.

This thesis I dedicate to my parents (Ramli Darasah and Nurdeli) who always support me for every single step I make, pray for me and help me when I am down and upset. Papa, Mama, thank you for being such great parents. Thanks to my brother, who is always there to support me and always listen to my stories. Thanks to Djoko Darmanto who is always there for me and supporting me in every way. This is something that I can give to you as a prove that you can count on me. Thanks for the trust you gave me that become my strength and confidence to complete this thesis.

Thanks to all of my friends in Malaysia for supporting me and for cheering up and accompany me along pass 3 years, it was fun to know you all. With you all, I know I am not alone, you all my family. Thanks to all of my friends in Indonesia for supporting me, I know this is not easy being a student in two different universities and different countries but I can show you this is extremely good experience that I can share with all of you. I hope this can be a good spirit to all of you that we can do anything as long as we put some efforts on it and believe that Allah always be with us.

Eka Giyanti Puteri Ramli

September 2011

# TABLE OF CONTENTS

	<b>Page</b>
TITTLE	i
CANDIDATE'S DECLARATION	ii
ABSTRACT	iii
ACKNOWLEDGEMENTS	iv
TABLE OF CONTENTS	v
LIST OF TABLES	x
LIST OF FIGURES	xiii
LIST OF SYMBOLS, ABBREVIATIONS OR NOMENCLATURES	xiv
LIST OF APPENDICES	xv
CHAPTER ONE. INTRODUCTION AND AIMS OF STUDY	1
1.1 Introduction	1
1.1.1 Bioavailability by oral route	1
1.1.2 Nanosuspensions - the formulation approach to overcoming poor solubility	2
1.1.2.1 Definition	2
1.1.2.2 Properties of nanosuspensions	2
1.1.2.3 Production of nanosuspensions - an overview	4
1.1.2.4 Production of nanosuspensions - Large scale production, scaling up issues	8
1.1.2.5 Final formulations of drug nanosuspensions	9
1.1.2.6 Production of nanosuspensions - Products on the market/in clinical phase	10
1.1.3 Conclusion and perspectives	12
1.2 Aims of study	12